Very low dose warfarin therapy prevents thrombosis In patients receiving cilemuihi"iipj" ;'ili Ii venous catheter Anticoagulation with standard dose warfarin is associated with a risk of haemorrhage, It has been suggested that smaller doses could prevent thrombi, but not prolong prothrombin times. This theory was evaluated in an open prospective, pilot study. 42 patients scheduled to receive chemotherapy via a central venous catheter received warfarin I mg daily begun 3 days before catheterisation and continued for 90 days, or until thrombus formation occurred. These patients were compared with 40 patients who were scheduled to receive chemotherapy via a central venous catheter, but who did not receive warfarin. Significantly fewer warfarin-treated patients developed venogram-confirmed thrombosis than controls (41's 15, respectively). Prothrombin times for the 3 thromboplastins, partial thromboplastin times and factor II, VII, IX and X levels were not affected by warfarin administration. For both the treated and control groups, patients who developed thromboses had lower partial thromboplastin times than the other members of the group (25.5 I'S 28 and 23.6 I'S 27.2, respectively). 'Clearly, ... there is a protective activit)' associated with this very-low-dose warfarin therapy, and this can exist without imposing a coagu!opathy.' Bern MM. .1.1. Wallach SR. Bothe .-\. Benolli P:"J. et al. Very 10" of "artarin can prnent thrombosis in central \L'nous of Internal Medicine 15 Mar 1990 "." 0156-270J/90/0J31-0009/0S01.00/0 C> ADlS has 9 INPHARMA® 31 Mllr 1990 _

Very low dose warfarin therapy prevents thrombosis

Download PDF Report

Upload
lamtruc
View
212
Download
0

Embed Size (px)

Citation preview

Page 1: Very low dose warfarin therapy prevents thrombosis

Very low dose warfarin therapy prevents thrombosis In patients receiving cilemuihi"iipj" ;'ili Ii ~~::!!'!!! venous catheter

Anticoagulation with standard dose warfarin is associated with a risk of haemorrhage, It has been suggested that smaller doses could prevent thrombi, but not prolong prothrombin times. This theory was evaluated in an open prospective, pilot study.

42 patients scheduled to receive chemotherapy via a central venous catheter received warfarin I mg daily begun 3 days before catheterisation and continued for 90 days, or until thrombus formation occurred. These patients were compared with 40 patients who were scheduled to receive chemotherapy via a central venous catheter, but who did not receive warfarin.

Significantly fewer warfarin-treated patients developed venogram-confirmed thrombosis than controls (41's 15, respectively). Prothrombin times for the 3 thromboplastins, partial thromboplastin times and factor II, VII, IX and X levels were not affected by warfarin administration. For both the treated and control groups, patients who developed thromboses had lower partial thromboplastin times than the other members of the group (25.5 I'S 28 and 23.6 I'S

27.2, respectively).

'Clearly, ... there is a protective activit)' associated with this very-low-dose warfarin therapy, and this ad~'antage can exist without imposing a coagu!opathy.'

Bern MM. Lo~,ch .1.1. Wallach SR. Bothe .-\. Benolli P:"J. et al. Very 10" do~e~ of "artarin can prnent thrombosis in central \L'nous l'atheter~. -\nnal~ of Internal Medicine II~: -t~3--t~8. 15 Mar 1990 "."

0156-270J/90/0J31-0009/0S01.00/0 C> ADlS has

9 INPHARMA® 31 Mllr 1990 _